Description
Methylethylpyridinol Pharmacodynamics
Angioprotector, decreases the permeability of the vascular wall, is an inhibitor of free radical processes, an antihypoxant and antioxidant.
It reduces blood viscosity and platelet aggregation, increases the content of cyclic nucleotides (cAMP and cGMP) in platelets and brain tissue, has fibrinolytic activity, reduces the permeability of the vascular wall and the risk of hemorrhages, promotes their resorption. Dilates coronary vessels, in the acute period of myocardial infarction limits the size of the focus of necrosis, improves the contractility of the heart and the function of its conduction system. At high blood pressure it has a hypotensive effect. In acute ischemic disorders of cerebral circulation it reduces the severity of neurological symptoms, increases tissue resistance to hypoxia and ischemia.
It has retinoprotective properties, protects the retina from the damaging effects of high intensity light, promotes the resorption of intraocular hemorrhages, improves the microcirculation of the eye.
Indications
As part of complex therapy: consequences of cerebral circulation disorders of ischemic and hemorrhagic nature, CHT, postoperative period of epi- and subdural hematomas; acute myocardial infarction, prevention of reperfusion syndrome, unstable angina.
Subconjunctival and intraocular hemorrhage, angioretinopathy (including diabetic), chorioretinal dystrophy (including Atherosclerotic genesis), dystrophic keratitis, retinal vascular thrombosis, complications of myopia, protection of the cornea (when wearing contact lenses) and the retina from high intensity light (laser and solar burns, in laser coagulation), corneal trauma, inflammation and burns, cataract (including prophylaxis for people over 40 years of age), and therapeutic measures. prophylaxis in patients older than 40 years old), surgical eye interventions, post-surgical conditions after glaucoma with choroidal detachment.
Contraindications
Hypersensitivity, pregnancy.
Usage during pregnancy and lactation.
It is contraindicated in pregnancy.
Dosage and administration
- If used in neurology and cardiology – by IV drops (20-40 drops/minute), 20-30 ml of 3% solution (600-900 mg) 1-3 times a day for 5-15 days (the drug is diluted in 200 ml of 0.9% NaCl solution or 5% dextrose solution beforehand). The duration of treatment depends on the course of the disease. Later it is transferred to intravenous injection – 3-5 ml of 3% solution 2-3 times daily for 10-30 days.
- In ophthalmology – subconjunctival or parabulbar, once daily or every other day.
- Subconjunctival – 0.2-0.5 ml of 1% solution (2-5 mg), parabulbar – 0.5-1 ml of 1% solution (5-1 mg). Treatment duration is 10-30 days; the course may be repeated 2-3 times a year.
- If necessary, retrabulbar treatment with 0.5-1 ml of 1% solution once a day for 10-15 days.
- To protect retina during laser coagulation (including limiting and destructive coagulation of tumors) – parabulbar or retrobulbar 0.5-1 ml of 1% solution 24 hours and 1 hour before coagulation, and then in the same doses (0.5 ml of 1% solution) 1 time a day for 2-10 days.
